Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampyra for upper limb dysfunction in multiple sclerosis
ACTRN12613000331730Phase 4Not yet recruiting
- Sponsor
- Austin Health
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dalfampridine in multiple sclerosis (MS) (3 arms), sponsored by Austin Health. Primary endpoint: Upper limb function using time to complete 9-hole peg test. Planned start Jul 2013; status: not yet recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12613000331730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000331730.